Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | NX-5948 + Venetoclax |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| NX-5948 | NX5948|NX 5948 | BTK inhibitor 39 | NX-5948 is a chimeric targeting molecule (CTM) comprised of a BTK binding element linked to Cereblon (CRBN), which potentially induces degradation of BTK and inhibition of tumor growth (Blood 2021 138 (Supp 1):2251). | |
| Venetoclax | Venclexta | ABT-199|RG7601|GDC-0199|ABT119|Venclyxto | BCL2 inhibitor 29 | Venclexta (venetoclax) is a BH3-mimetic that binds to and inhibits BCL2, resulting in increased tumor cell apoptosis (PMID: 26589495, PMID: 25048785). Venclexta (venetoclax) is FDA approved for use in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and in combination with chemotherapy in patients 75 years old or older with newly-diagnosed acute myeloid leukemia (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07520006 | Phase Ib/II | NX-5948 + Venetoclax NX-5948 + Obinutuzumab + Venetoclax NX-5948 + Rituximab + Venetoclax | Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies | Recruiting | USA | 0 |